Alcon Inc. research snapshot
ALC AI stock analysis reads Alcon as the global eye-care specialist whose Surgical and Vision Care businesses serve recurring demand from cataract surgery, contact lenses, dry eye, and surgical consumables. At the August 2, 2026 data cutoff, ALC last closed near $68.94 on July 31, 2026 with a market capitalization of approximately $33.4 billion. First-quarter 2026 sales rose 10 percent reported, or 6 percent constant currency, to $2.685 billion, and management kept 2026 constant-currency sales growth guidance at 5 percent to 7 percent while raising core diluted EPS growth guidance to 10 percent to 13 percent. Core operating margin improved to 21.2 percent, but reported results carried efficiency, impairment, and tariff costs that cut GAAP diluted EPS to $0.39. The investment case depends on product launches, margin execution, tariffs, currency, and disciplined capital allocation. This page is informational research only and is not investment advice.
Current price
$68.94
Market cap
$33.4 billion
AI score
67 / 100
Rating
Durable eye-care franchise with improving core profitability, a reasonable forward valuation, and execution and tariff risk
Trend status
Below the 52-week high and the 200-day moving average, with a range-bound chart awaiting the August 10 earnings report
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Alcon sells surgical equipment, implantables, consumables, contact lenses, and ocular-health products that support recurring eye-care demand across clinics, hospitals, optometrists, and consumers. | High |
| Moat | Clinical evidence, regulatory approvals, surgeon training, installed equipment, trusted brands, global distribution, and manufacturing know-how create switching costs, though large medical-device competitors remain active. | Medium-high |
| Management | Management is investing behind Unity, Tryptyr, PanOptix Pro, Precision7, surgical equipment, and Vision Care launches while returning capital through dividends and a new $1.5 billion buyback. The test is whether these investments support margins and cash generation. | Medium-high |
| Financial trend | FY2025 revenue was $10.401 billion, up 4.94 percent, with $980 million of net income and $1.728 billion of free cash flow. Q1 2026 sales rose 10 percent reported to $2.685 billion, and core operating margin reached 21.2 percent. | High |
| Valuation | At $68.94, precise checks using TTM GAAP figures indicate about 41.28x earnings, 1.52x book value, and 19.70x free cash flow per share, with a forward PE near 18. Core earnings are higher than GAAP earnings, so the chosen definition matters. | Medium-high |
| Technical trend | ALC was below its $90.41 52-week high and the $74.82 200-day moving average, and near the $67.28 50-day moving average. The chart is range-bound until price and volume confirm a break from the mid-to-high $60s area. | Medium |
| Risk level | Risk is medium-high because procedure demand can soften, launch spending and tariffs can pressure margins, currency can move reported results, and competition can challenge pricing or adoption. | High |
| AI confidence | High for audited and filed data, market-cap math, and stated guidance; medium for scenario analysis and technical trade setups. | High data confidence |
| Investment certainty | Medium certainty. ALC is a research candidate, not a universal buy, because execution and market valuation still determine the outcome. | Medium |
ALC AI stock forecast
The ALC AI stock forecast uses scenario ranges rather than a single price target. A three-year model built on FY2026 consensus core diluted EPS of about $3.47 produced approximately $61 in a bearish case, $92 in a base case, and $122 in a bullish case. These outputs are conditional valuation scenarios, not predictions or recommendations.
$110 to $125
More likely if Unity, Tryptyr, PanOptix Pro, and Precision7 sustain growth, cataract and contact-lens demand remains healthy, core EPS compounds near double digits, margins expand despite tariffs, and investors assign a premium medical-technology multiple.
$85 to $95
More likely if sales grow around managements 5 percent to 7 percent constant-currency outlook, core EPS compounds near 8 percent to 9 percent, free cash flow remains solid, and the market applies a low-20s core earnings multiple.
$55 to $65
More likely if procedure volumes weaken, new products miss adoption goals, tariffs or currency pressure margins, competition intensifies, or investors rerate the stock toward a high-teens earnings multiple.
ALC AI technical analysis
ALC AI technical analysis is a dated August 2, 2026 snapshot, not a live trading signal. The last close was $68.94 on July 31, 2026. The 52-week range is $61.84 to $90.41, the 50-day moving average is $67.28, and the 200-day moving average is $74.82. Price is below the 200-day average and near the 50-day average, so check a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $68.94 | StockAnalysis quote snapshot at the stated cutoff. Confirm the live quote before acting. |
| Near support | $61.84 to $65 | The 52-week low and the June and July low area are a risk reference, not a guaranteed floor. |
| Near resistance | $70 to $72 | Recent July rebound highs sit in this zone. A sustained move above it on stronger volume would improve the short-term structure. |
| Key resistance | $74.82 | The 200-day moving average is a reference for trend reassertion and needs volume and fundamental support to reclaim. |
| Long-term resistance | $90.41 | The 52-week high is a clear longer-term reference and needs fundamental and volume confirmation to reclaim. |
| Moving averages | 50-day $67.28; 200-day $74.82 | The 200-day average sits above the 50-day average, consistent with a broader downtrend that needs a reclaim. |
| Momentum and volume | RSI near 53; volume confirmation needed | 20-day average volume is about 2.3 million shares. A breakout is more credible when volume is above that average and earnings or guidance support it. |
| Volatility | $61.84 to $90.41 52-week range; beta 0.70 | Clinical product news, guidance, tariff and currency changes, and macro conditions can materially reset expectations. |
| Invalidation | Sustained close below $61.84 | A decisive move below the 52-week low invalidates a range-support setup and calls for a fresh review. |
ALC AI trading strategy
The ALC AI trading strategy is a rules-based research framework, not personalized investment advice. Combine a current chart check with the August 10, 2026 earnings report, procedure volumes, launch adoption, margins, currency, tariffs, and position-size limits.
Wait for ALC to reclaim $70 to $72 and then the 200-day moving average near $74.82 with above-average volume, and confirm that live moving averages support the move. Reassess after the August 10, 2026 earnings report.
Use a pre-defined loss limit. A sustained close below $61.84 or deteriorating guidance should invalidate the setup.
If price tests $61.84 to $65 without a new fundamental impairment, compare the reaction with surgical procedure trends, Vision Care growth, free cash flow, and tariff or currency updates.
Do not average down automatically. A break below the 52-week low or a negative earnings reset requires reassessment.
Track Surgical and Vision Care sales, Unity, Tryptyr, PanOptix Pro, and Precision7 adoption, constant-currency growth, core operating margin, free cash flow, net debt, buyback execution, and 2026 guidance.
Reduce confidence if growth depends on currency or short-term pricing while core margins, procedure volumes, and cash conversion weaken.
Investment research summary
Alcon earns money by supplying eye-care professionals and consumers with surgical systems, implants, consumables, contact lenses, and ocular-health products that address recurring clinical and vision needs.
The moat rests on clinical trust, regulatory know-how, surgeon training, installed equipment, product ecosystems, global distribution, and brands. It must be renewed through product innovation.
The thesis can fail if procedure volumes slow, surgeons or consumers resist new products, competitors gain share, tariffs and currency overwhelm pricing, or launch spending does not turn into durable cash returns.
Management is allocating capital to product launches, R&D, dividends, and a new three-year share repurchase authorization of up to $1.5 billion. The scorecard is organic growth, margin discipline, cash conversion, and return on invested capital.
Aging populations, cataract procedures, myopia management, contact-lens use, dry-eye treatment, and technology upgrades can support demand, though reimbursement and health-system budgets affect timing.
The price implies confidence that earnings quality and launch momentum will improve. Separating GAAP from core earnings matters, and a margin of safety depends on free cash flow durability and not assuming a premium multiple is permanent.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ALC price and 52-week range | $68.94 close on July 31, 2026; $61.84 to $90.41 range | StockAnalysis quote and statistics snapshot | August 2, 2026 |
| Market capitalization | $33.38 billion reported; $33.62 billion verified as $68.94 x 487.7 million shares | StockAnalysis statistics and financial_rigor.py | August 2, 2026 |
| FY2025 revenue | $10.401 billion, up 4.94 percent year over year | Alcon 2025 Form 20-F and StockAnalysis cross-check | August 2, 2026 |
| FY2025 net income and free cash flow | $980 million net income and $1.728 billion free cash flow | Alcon FY2025 results and StockAnalysis cross-check | August 2, 2026 |
| Q1 2026 sales | $2.685 billion, up 10 percent reported and 6 percent constant currency | Alcon Q1 2026 results release | August 2, 2026 |
| Q1 2026 core results | Core diluted EPS $0.85, up 16 percent; core operating margin 21.2 percent, up 0.4 points | Alcon Q1 2026 results release | August 2, 2026 |
| Cash and debt, Q1 2026 | $1.659 billion cash and short-term investments; $5.262 billion total debt; $3.603 billion net debt | Alcon Q1 2026 interim report and StockAnalysis cross-check | August 2, 2026 |
| 2026 outlook | 5 percent to 7 percent constant-currency sales growth, core operating margin up 70 to 170 bps, and 10 percent to 13 percent core diluted EPS growth | Alcon Q1 2026 results release | August 2, 2026 |
| Analyst consensus | Buy rating from 26 analysts with an average target of $87.32 and a range of $62 to $107.40 | StockAnalysis analyst forecast | August 2, 2026 |
| Valuation check | 41.28x TTM GAAP EPS, 1.52x book value, 19.70x free cash flow per share, 0.33 percent dividend yield, forward PE near 18 | financial_rigor.py valuation verification and StockAnalysis statistics | August 2, 2026 |
This ALC AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after earnings, product news, tariff or currency updates, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
